Page 3 - Interim Data News Today

Sasol, a major Energy firm in South Africa, features upward momentum, but a somewhat bearish chart. Read what investors should know about SSL stock here.

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual MeetingSOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy an...

Investegate announcements from SOTIO Biotech, Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting

Investegate announcements from SOTIO Biotech, Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch gezielte Einwirkung auf die Tumormikroumgebung (TME), gibt bekannt

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch gezielte Einwirkung auf die Tumormikroumgebung (TME), gibt

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT SOUTH SAN FRANCISCO, C

Published: Mar 11, 2021 By Alex Keown Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characteri...